Relationship Between Pharmacokinetics and Safety of Vismodegib - OPTIVISMO-1
Status:
Recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
Vismodegib (ERIVEDGE®) at the standard dose of 150 mg/day orally is indicated for the
treatment of advanced Basal Cell Carcinoma (BCC) and is associated with many adverse effects.
Cramps, alopecia, dysgeusia, weight loss and others observed in clinical practice, compromize
compliance and often lead to treatment discontinuation. Currently, it is the only drug
available in this indication. Our main objective is to assess the relationship between plasma
concentrations of vismodegib, and the occurrence of adverse effects within 6 months of
inclusion in the study.